Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 7/20 | 0.42 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.34 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798693 | 1.00 | SLC13A5 (0.42) | SLC13A5SLC13A2SLC13A3ACSS2CDC7 | |
| SCHEMBL5862668 | 0.85 | SLC13A5 (0.32) | SLC13A5 | |
| SCHEMBL2801656 | 0.83 | SLC13A5 (0.42) | SLC13A5SLC13A2SLC13A3ACSS2MAPT | |
| SCHEMBL2801659 | 0.83 | SLC13A5 (0.42) | SLC13A5SLC13A2SLC13A3ACSS2MAPT | |
| SCHEMBL7454862 | 0.82 | SLC13A5 (0.30) | SLC13A5 | |
| SCHEMBL15484370 | 0.78 | SLC13A5 (0.33) | SLC13A5ACSS2 | |
| SCHEMBL6623394 | 0.77 | SLC13A5 (0.33) | SLC13A5SLC13A2SLC13A3GAA | |
| SCHEMBL6787926 | 0.73 | KDM4E (0.32) | — | |
| SCHEMBL25649981 | 0.73 | SLC22A12 (0.37) | ACSS2MAPT | |
| SCHEMBL7460345 | 0.72 | TSHR (0.35) | SLC13A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025077773-A1 | NOVEL TYPE I TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20100168426-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | IPSEN/S.C.R.A.S. (ANDRE BOURGOUIN) (FR) | 2010-07-01 | — | — | US | disclosed |
| US-7705155-B2 | Processes for the production of useful intermediates | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090247563-A9 | Novel Processes for the Production of Useful Intermediates | IPSEN/S.C.R.A.S. (ANDRE BOURGOUIN) (FR) | 2009-10-01 | — | — | US | disclosed |
| US-20070167475-A1 | Novel Processes for the Production of Useful Intermediates | IPSEN/S.C.R.A.S. (ANDRE BOURGOUIN) (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1794127-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033011-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2006-03-30 | — | — | WO | disclosed |
| EP-0946566-B1 | PRO-DRUGS AND COUNTERPARTS OF CAMPTOTHECIN, THEIR APPLICATION AS MEDICINES | SOD CONSEILS RECH APPLIC (FR) | 2003-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167475-A1 | Novel Processes for the Production of Useful Intermediates | PGD, TALDO1, COASY | SLC13A5 2256/4885SLC13A2 3250/4885SLC13A3 3165/4885 |
| US-20090247563-A9 | Novel Processes for the Production of Useful Intermediates | PGD, TALDO1, COASY | SLC13A5 2256/4885SLC13A2 3250/4885SLC13A3 3165/4885 |
| US-20100168426-A1 | NOVEL PROCESSES FOR THE PRODUCTION OF USEFUL INTERMEDIATES | PGD, TALDO1, COASY | SLC13A5 2256/4885SLC13A2 3250/4885SLC13A3 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.